Balance Sheet
Cash Flow Statement
Asset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in CashChange in IntangiblesChange in InventoryChange in ReceivablesChange in TaxesDepreciation & Amortization (CF)Exchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Sunshine Biopharma (SBFM) Cash from Investing Activities (2016 - 2025)

Sunshine Biopharma (SBFM) has disclosed Cash from Investing Activities for 9 consecutive years, with -$118295.0 as the latest value for Q3 2025.

  • For the quarter ending Q3 2025, Cash from Investing Activities rose 82.36% year-over-year to -$118295.0, compared with a TTM value of -$1.2 million through Sep 2025, up 43.03%, and an annual FY2024 reading of -$2.3 million, down 253.71% over the prior year.
  • Cash from Investing Activities was -$118295.0 for Q3 2025 at Sunshine Biopharma, up from -$491778.0 in the prior quarter.
  • Across five years, Cash from Investing Activities topped out at $18859.0 in Q3 2023 and bottomed at -$14.6 million in Q4 2022.
  • Average Cash from Investing Activities over 4 years is -$1.5 million, with a median of -$354267.0 recorded in 2023.
  • The sharpest move saw Cash from Investing Activities surged 98.16% in 2023, then tumbled 3655.86% in 2024.
  • Year by year, Cash from Investing Activities stood at -$14.6 million in 2022, then soared by 98.16% to -$269230.0 in 2023, then plummeted by 63.17% to -$439304.0 in 2024, then surged by 73.07% to -$118295.0 in 2025.
  • Business Quant data shows Cash from Investing Activities for SBFM at -$118295.0 in Q3 2025, -$491778.0 in Q2 2025, and -$176024.0 in Q1 2025.